Birth records from Swiss married couples analyzed over of the past 35 years reveal an aging of first-time mothers by 5.1 years while the interpregnancy interval has shortened

RésuméIntroduction : Le travail de thèse est un article publié dans le journal « Fertility & Sterility » s'intitulant « Birth records from Swiss married couples analyzed over the past 35 years reveal an aging of first-time mothers by 5.1 years while the interpregnancy interval has shortened ».Méthodes : Les données concernant l'âge auquel les femmes mariées donnaient naissance ont été obtenues de l'Office fédéral de la statistique. Nous avons examiné la période allant de 1969 à 2006. Cet intervalle de temps choisi nous a permis de prendre en considération un total de 2'716'370 naissances. L'âge moyen des parturientes à la naissance de leur 1er, 2ème et 3ème enfant a été calculé pour chaque année à l'aide du logiciel Excel. Grâce à ces données on a pu obtenir les intervalles inter-gestationnels théoriques entre le 1er et 2ème enfant, ainsi qu'entre le 2ème et 3ème enfant.Résultats : Nous pouvons constater que l'intervalle inter-gestationnel théorique entre la première et la deuxième grossesse était de 23.2 mois en 1969 et passait à 13.0 mois en 2006. L'intervalle compris entre la deuxième et la troisième grossesse passait de 22.4 mois en 1969 à 7.9 mois en 2006. Notre analyse suggère donc que c'est le facteur social qui exerce un effet plus important que le facteur biologique sur les intervalles inter-gestationnels, car ces intervalles diminuaient malgré l'augmentation de l'âge des mères à la naissance.

First Case of Natural Infection in Pigs: Review of Trypanosoma cruzi Reservoirs in Mexico

An epidemiological research project was performed in the State of Morelos including collection of samples for blood smears and culture, serological tests, and xenodiagnoses from a total of 76 domestic and peridomestic mammals. Two strains of Trypanosoma cruzi were isolated by haemocultures; one from a pig (Sus scrofa), the first case of natural infection reported in Mexico, and the other from a dog (Canis familiaris). This study summarizes current information in Mexico concerning confirmed reservoirs of T. cruzi

Encoding dysfunctions in a dynamic-static paradigm for visuospatial working memory in first-episode psychosis patients: a 2-year follow-up study.

Aim: To investigate static and dynamic visuospatial working memory (VSWM) processes in first-episode psychosis (FEP) patients and explore the validity of such measures as specific trait markers of schizophrenia. Methods: Twenty FEP patients and 20 age-, sex-, laterality- and education-matched controls carried out a dynamic and static VSWM paradigm. At 2-year follow up 13 patients met Diagnostic and Statistical Manual (of Mental Health Disorders) - Fourth Edition (DSM-IV) criteria for schizophrenia, 1 for bipolar disorder, 1 for brief psychotic episode and 5 for schizotypal personality disorder. Results: Compared with controls, the 20 FEP patients showed severe impairment in the dynamic VSWM condition but much less impairment in the static condition. No specific bias in stimulus selection was detected in the two tasks. Two-year follow-up evaluations suggested poorer baseline scores on the dynamic task clearly differentiated the 13 FEP patients who developed schizophrenia from the seven who did not. Conclusions: Results suggest deficits in VSWM in FEP patients. Specific exploratory analyses further suggest that deficit in monitoring-manipulation VSWM processes, especially involved in our dynamic VSWM task, can be a reliable marker of schizophrenia.

The Vth "prapāṭhaka" of the Vādhūlaśrautasūtra

Résumé/Summary : La thèse présentée ici et intitulée The Vth prapāṭhaka of the Vādhūlaśrautasūtra consiste en une édition critique suivie d'une traduction et d'un commentaire du Ve chapitre (prapāṭhaka) du Vādhūlaśrautasūtra consacré au sacrifice animal dit "indépendant" (nirūḍhapaśubandha) de la religion védique. La traduction et le commentaire font l'objet du premier tome de cette thèse et l'édition critique celui du second tome. Le commentaire qui suit la traduction dans le premier tome ne se limite pas aux particularités de la version Vādhūla du nirūḍhapaśubandha. Il s'agit plutôt d'une série de monographies consacrées à des aspects particuliers du sacrifice animal décrit par les Veda, voire à des questions plus générales d'exégèse des textes védiques. Dans ma conclusion à la fin du premier tome je discute aussi de l'antiquité de l'école Vādhūla et de sa place dans le corpus textuel de la branche Taittirīya du Yajurveda noir. THE PRESENT THESIS, ENTITLED THE VTH PRAPAṭHAKA OF THE VADHULASRAUTASUTRA, CONSISTS IN A CRITICAL EDITION, FOLLOWED BY A TRANSLATION AND A COMMENTARY, OF THE VTH CHAPTER (PRAPAṭHAKA) OF THE VADHULASRAUTASUTRA. THE VTH PRAPAṭHAKA IS DEDICATED TO THE DESCRIPTION OF THE SO-CALLED "INDEPENDENT" ANIMAL SACRIFICE (NIRUḍHAPASUBANDHA) IN VEDIC RELIGION. THE TRANSLATION AND THE COMMENTARY ARE PRESENTED IN THE FIRST VOLUME, WHILE THE CRITICAL EDITION MAKES UP THE SECOND VOLUME. The commentary that follows the translation in the first volume is not concerned only with the peculiarities of the Vādhūla version of the nirūḍhapaśubandha. It is more a series of short monographs related to particular aspects of the animal sacrifice described in the Veda and to problems of exegesis of Vedic texts. In my conclusion at the end of the first volume, I also discuss the ancientness of the Vādhūla school, as well as its place within the corpus of Taittirīya texts.

VeriStrat(®) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528.

BACKGROUND: VeriStrat(®) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. The main objective of our retrospective study was to evaluate the role of VS as a marker of overall survival (OS) in patients treated with erlotinib and bevacizumab in the first line. PATIENTS AND METHODS: Patients were pooled from two phase II trials (SAKK19/05 and NTR528). For survival analyses, a log-rank test was used to determine if there was a statistically significant difference between groups. The hazard ratio (HR) of any separation was assessed using Cox proportional hazards models. RESULTS: 117 patients were analyzed. VeriStrat classified patients into two groups which had a statistically significant difference in duration of OS (p=0.0027, HR=0.480, 95% confidence interval: 0.294-0.784). CONCLUSION: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. Further work is needed to study the predictive role of VeriStrat for erlotinib and bevacizumab in chemotherapy-untreated patients.

Six years of denosumab treatment in postmenopausal women with osteoporosis: results from the first three years of the freedom extension

Background/Purpose: Denosumab (DMAb) is an approved therapy for the treatment of postmenopausal women with osteoporosis at increased risk for fracture. A favorable risk/benefit profile was demonstrated in the pivotal, 3-year FREEDOM trial (Cummings et al NEJM 2009). The open-label, active-treatment FREEDOM Extension study is investigating the efficacy and safety of DMAb for up to 10 years. The Extension trial enrolled women who had received DMAb or placebo in FREEDOM and provides an opportunity to evaluate the long-term efficacy and safety of continuous DMAb treatment (long-term group), and to replicate the DMAb findings observed in FREEDOM (cross-over group). Here, we report the results from the first 3 years of the Extension, representing up to 6 continuous years of DMAb exposure.Methods: During the Extension, each woman is scheduled to receive 60 mg DMAb every 6 months and supplemental calcium and vitamin D daily. For the analyses reported here, women from the FREEDOM DMAb group received 3 more years of DMAb for a total of 6 years of exposure (long-term group) and women from the FREEDOM placebo group received 3 years of DMAb exposure (cross-over group).Results: Of the 5928 women eligible for the Extension, 4550 (77%) enrolled (N_2343 long-term; N_2207 cross-over). In the long-term group, further significant mean increases in bone mineral density (BMD) occurred 4044 for cumulative 6-year gains of 15.2% at the lumbar spine and 7.5% at the total hip (Figure). During the first 3 years of DMAb treatment during the Extension, the cross-over group had significant mean gains in BMD at the lumbar spine (9.4%) and total hip (4.8%), similar to those observed in the long-term DMAb group during the first 3 years of FREEDOM (lumbar spine, 10.1%; total hip, 5.7%). Serum CTX was rapidly and similarly reduced after the 1st (cross-over) or 7th (long-term) DMAb dose with the characteristic attenuation observed at the end of the dosing period. In the cross-over group, yearly incidences of new vertebral and nonvertebral fractures were lower than in the FREEDOM placebo group. Fracture incidence remained low in the long-term group. Incidences of adverse events (AEs) and serious AEs did not increase over time with DMAb treatment. There were 2 subjects with AEs adjudicated to ONJ in the cross-over group and 2 in the long-term group. Both cases in the cross-over group healed completely and without further complications; 1 of these subjects continues to receive DMAb. Both women in the long-term group continue to be followed. No atypical femur fractures have been observed to date. Figure. Percent changes in bone mineral density during FREEDOM and the Extension Conclusion: DMAb treatment for 6 continuous years (long-term group) remained well tolerated, maintained reduced bone turnover, and continued to significantly increase BMD. Fracture incidence remained low. DMAb treatment for 3 years in the cross-over group reproduced the original observations in FREEDOM.

Study on the Elimination of Angiostrongylus costaricensis First Stage Larvae in the Experimental Infection of Swiss Mice

Abdominal angiostrongylosis is a nematode infection of wild rodents. Human infection may result in severe abdominal disease and has been reported from several countries in the Americas. The domestic mouse, Mus musculus, has not been found with natural infection and, like other urban rodents, should not be considered a natural host for Angiostrongylus costaricensis. Quantification of parasitic forms released for transmission may better express the coevolutionary status in parasite-host relationship. With this objective, five groups of experimentally infected Swiss mice were followed for up to 155 days post-infection (PI) days and the quantification of first stage larvae (L1) output revealed: an irregular elimination of L1 and a huge variation in the patency period (1 to 114 days) and in the number of L1 eliminated daily by individual animals (1 to 6340 L1/g). Overall mortality was 72% (range: 28% to 100%) at seven weeks PI. In conclusion, abdominal angiostrongylosis in M. musculus presents high mortality and a very variable and irregular elimination of L1 in feces.

MEVA-Ambiental: MEtodologia per a la Valoració de l'Aprenentatge. Centrada en l'educació ambiental

Aquest projecte abasta el disseny i el desenvolupament d’un model prototípic de Metodologia per a la Valoració de l’Aprenentatge Ambiental, a la qual anomenem “MEVA-Ambiental”. Per a fer possible aquesta fita ens hem basat en fonaments ontològics i constructivistes per representar i analitzar el coneixement a fi de poder quantificar l’Increment de Coneixement (IC). Per nosaltres l’IC esdevé un indicador socio-educatiu que ens servirà per a determinar l’efectivitat dels tallers d’educació ambiental en percentatge. En procedir d’aquesta manera, les qualificacions resultats poden es poden prendre com punt de partida per a desenvolupar estudis en el temps i comprendre com “s’ancora” el nou coneixement a l’estructura cognitiva dels aprenents. Més enllà del plantejament teòric de mètode, també proveïm la solució tècnica que mostra com n’és de funcional i d’aplicable la part empírica metodològica. A aquesta solució que hem anomenat “MEVA-Tool”, és una eina virtual que automatitza la recollida i tractament de dades amb una estructura dinàmica basada en “qüestionaris web” que han d’emplenar els estudiants, una “base de dades” que acumula la informació i en permet un filtratge selectiu, i més “Llibre Excel” que en fa el tractament informatiu, la representació gràfica dels resultats, l’anàlisi i conclusions.

First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).

BACKGROUND: Oral temozolomide has shown similar efficacy to dacarbazine in phase III trials with median progression-free survival (PFS) of 2.1 months. Bevacizumab has an inhibitory effect on the proliferation of melanoma and sprouting endothelial cells. We evaluated the addition of bevacizumab to temozolomide to improve efficacy in stage IV melanoma. PATIENTS AND METHODS: Previously untreated metastatic melanoma patients with Eastern Cooperative Oncology Group performance status of two or more were treated with temozolomide 150 mg/m(2) days 1-7 orally and bevacizumab 10 mg/kg body weight i.v. day 1 every 2 weeks until disease progression or unacceptable toxicity. The primary end point was disease stabilisation rate [complete response (CR), partial response (PR) or stable disease (SD)] at week 12 (DSR12); secondary end points were best overall response, PFS, overall survival (OS) and adverse events. RESULTS: Sixty-two patients (median age 59 years) enrolled at nine Swiss centres. DSR12 was 52% (PR: 10 patients and SD: 22 patients). Confirmed overall response rate was 16.1% (CR: 1 patient and PR: 9 patients). Median PFS and OS were 4.2 and 9.6 months. OS (12.0 versus 9.2 months; P = 0.014) was higher in BRAF V600E wild-type patients. CONCLUSIONS: The primary end point was surpassed showing promising activity of this bevacizumab/temozolomide combination with a favourable toxicity profile. Response and OS were significantly higher in BRAF wild-type patients.

Anna Senyé, poeta

Anna Senyé, poeta és un treball que explora la vida i el treball literari d’una poeta catalana anònima. Anna Senyé Ramisa (Manlleu, 1881-Barcelona, 1956) fou una dona de caràcter aventurer que va tenir una vida poc convencional. Va escriure en diferents revistes i diaris catalans des de 1914 i durant la primera meitat del segle vint, tant com a poeta com a periodista i activista social, amb la publicació d’articles i manifestos en defensa dels drets dels animals. Senyé també participà en els Jocs Florals i va guanyar-hi premis en els celebrats a l’Escala i Molins de Rei. L’any 1922 va publicar el seu treball poètic en un volum, Remolinada. Els seus poemes mostren el seu amor pels animals i la natura, així com també el record de la infantesa a la seva vila natal. Presentem quatre retrats de l’escriptora: el ‘Retrat de la família’, el ‘Retrat de la dona’, el ‘de la poeta’ i finalment, el ‘Retrat de la viatgera’. Amb aquests retrats, els poemes d’Anna Senyé deixen de ser oblidats i la poeta passa a formar part de la genealogia d’escriptores catalanes. Paraules clau: Anna Senyé, poesia catalana, gènere i literatura.